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Disorders of sex development (DSD), previously referred to as intersex disorders, comprise
a variety of anomalies defined by congenital conditions in which chromosomal, gonadal, or an-
atomical sex is atypical. Besides issues such as gender assignment, clinical and diagnostic evalu-
ation, surgical and psychosocial management, and sex steroid replacement, the significantly
increased risk for developing specific types of malignancies is both clinically and biologically
relevant. This relates to germ-cell tumors specifically in DSD patients with hypovirilization or
gonadal dysgenesis. The presence of a well-defined part of the Y chromosome (known as the
GBY region) is a prerequisite for malignant transformation, for which the testis-specific protein
on the Y chromosome (TSPY ) is a likely candidate gene. The precursor lesions of these cancers
are carcinoma in situ (CIS)/intratubular germ-cell neoplasia unclassified (ITGCNU) in testicular
tissue and gonadoblastoma in those without obvious testicular differentiation. Most recently,
undifferentiated gonadal tissue (UGT) has been identified as the likely precursor for gonadoblas-
toma. The availability of markers for the different developmental stages of germ cells allows
detailed investigation of the characteristics of normal and (pre)malignant germ cells. Although
informative in a diagnostic setting for adult male patients, these markers – such as OCT3/4 –
cannot easily distinguish (pre)malignant germ cells from germ cells showing delayed maturation.
This latter phenomenon is frequently found in gonads of DSD patients, and may be related to
the risk of malignant transformation. Thus, the mere application of these markers might result
in over-diagnosis and unnecessary gonadectomy. It is proposed that morphological and histolog-
ical evaluation of gonadal tissue, in combination with OCT3/4 and TSPY double immunohisto-
chemistry and clinical parameters, is most informative in estimating the risk for germ-cell tumor
development in the individual patient, and might in future be used to develop a decision tree for
optimal management of patients with DSD.
Key words: germ-cell development; malignant transformation; CIS/ITGCNU; gonadoblastoma;
cancer risk; delayed maturation; diagnostic markers; prediction model.
Patients with specific forms of disorders of sex development (DSD), as defined re-
cently in the Consensus Statement on Management of Intersex Disorders1, have an
increased risk for development of cancers originating from the germ-cell lineage,
also known as germ-cell tumors (GCTs). Within this group of tumors, various entities
have been identified which are characterized by age at clinical presentation, histology,
clinical behavior, and genomic constitution.2 Based on these parameters, we proposed
a novel classification system in which five types of GCTs are distinguished. These are
summarized in Table 1, and are also recognized by the World Heath Organization.3 In
the context of DSD, only the type-II GCTs are of relevance; these are the seminom-
atous and non-seminomatous types of tumor. In the adult testis, these cancers are the
most frequent malignancy in Caucasian males of the age group 15–45 years, and are
showing an increasing incidence.4,5 The testicular dysgenesis syndrome (TDS) has
been suggested to be the underlying reason for the development of this type of
testicular cancer.6 TDS links various clinical observations, such as cryptorchidism, sub-
fertility/infertility, and an increased risk of cancer. These features have been suggested
to be the result of the same underlying mechanism. They are related to a suboptimal
testicular development, to environmental factors (such as xeno-estrogens and anti-
androgens), and possibly to genetic factors. The model of TDS is relevant in the context
of the increased risk of development of type-II GCTs in patients with DSD, as initially
proposed by Skakkebaek and co-workers (see below).
The type-II GCTs refer to seminomatous and non-seminomatous tumors. Histolog-
ically, the seminomatous tumors are composed of neoplastic primordial germ cells/
gonocytes. The non-seminomatous GCTs, which result from reprogramming of
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a seminomatous precursor cell, are subdivided into the stem-cell component embry-
onal carcinoma (EC) and the somatic and extra-embryonic elements, i.e., teratoma
(TE) and yolk-sac tumor (YST), choriocarcinoma (CH), and the germ line (see also
Figure 1A, right).2,3,7 It is of relevance to note that TE and YST can also be found in
the so-called type-I GCTs, which are predominantly diagnosed in neonates and infants.
However, these have a different cell of origin and chromosomal constitution.8–11
The precursor lesions of the type-II GCTs have been identified and characterized
to a certain extent. The most important observations in the context of DSD will be
discussed here. In order to understand the relevance of these findings, the normal
germ-cell development will be presented first.
NORMAL GERM-CELL DEVELOPMENT
During recent years our understanding of the pathobiology of type-II GCTs has
increased due the availability of specific markers that characterize germ cells at different
stages of their development and maturation. The process of germ-cell development is
strictly organized in both time and space.12 It starts during early intrauterine develop-
ment (weeks 5–7 in humans) in the proximal epiblast13 (see also Figure 1B). Primordial
germ cells (PGCs) divide and move along the hindgut to the genital ridges.14 At this
stage they show a number of unique characteristics. After their arrival in the genital
ridges, they are referred to as gonocytes, but morphologically they are still indistin-
guishable from PGCs. In addition, they show expression of the same genes and
proteins, including alkaline phosphatase, c-KIT, and OCT3/415 (Figure 1C, and see
below). During the subsequent steps of maturation, the germ cells lose their
Practice points
 DSD patients have an increased risk for type-II GCTs
 Type-II GCTs refer to the seminomatous and non-seminomatous GCTs
Table 1. Summary of the classification of germ cell tumors (GCTs) in five entities.
Type Histology Cell of origin Anatomical site
I TE/YST Embryonic GCa Midline
II SE/N PGC/gonocyteb Midlined
III SS Primary spermatocytec Testis
IV DC Parthogenote Ovary
V HM Androgenote Uterus
TE, teratoma; YST, yolk-sac tumor; SE, seminomatous GCT (seminoma of the testis, dysgerminoma of
the ovary and dysgenetic gonad and germinoma of the brain); N, non-seminoma (can be composed of
embryonal carcinoma, choriocarcinoma); SS, spermatocytic seminoma; DC, dermoid cyst; HM, hydatidi-
form mole; GC, germ cell; PGC, primordial germ cell.
a Not proven in all cases.
b Erased pattern of genomic imprinting.
c Paternal pattern of genomic imprinting.
d Predominantly the male gonad.
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embryonic characteristics, such as expression of OCT3/4. Initially OCT3/4 was iden-
tified as one of the regulatory elements in the differentiation of embryonic stem
cells16, but OCT3/4 expression is also present in PGCs and gonocytes and their ma-
lignant counterparts (see below). This may account for the capacity of early PGCs to
generate pluripotent stem cells2 (see also below).
Figure 1. (A) Summary of the precursor lesions for the type-II germ-cell tumors (GCTs), these being
carcinoma in situ/intratubular germ-cell neoplasia unclassified (CIS/ITGCNU) in the testis, and CIS/ITGCNU
or gonadoblastoma in the case of dysgenetic gonads. The malignant cells can be diagnosed on the basis of
immunohistochemical detection of OCT3/4, amongst other markers. These precursors will progress to
invasive GCTs, with the histology of either seminoma or the different non-seminomatous elements: embry-
onal carcinoma, teratoma, yolk-sac tumor and choriocarcinoma. Seminomatous cells can be reprogrammed
to embryonal carcinoma, the stem-cell component of the non-seminomas. Besides these histologies, the
germ-cell lineage has been identified recently. All CIS/ITGCNU are supposed to form an invasive cancer,
with a figure of about 50% being suggested for gonadoblastoma. (B) Schematic representation of the different
developmental steps in the intrauterine generation and development of the germ-cell lineage. The CIS/
ITGCNU cells mimic primordial germ cells (PGCs)/gonocytes regarding their morphology and marker ex-
pression profile, although they have an aberrant histological localization, i.e., under the tight junctions of
the Sertoli cells illustrated in (A). (C) Representative examples of immunohistochemical demonstration of
OCT3/4 in embryonic male gonads of 13 weeks’ gestational age (left) and 1 week postpartum. Note the
presence of OCT3/4-positive germ cells, with numbers declining at higher gestational age. The OCT3/4-pos-
itive germ cells after partus are located in the lumen of the seminiferous tubules, sometimes misdiagnosed as
CIS/ITGCNU.
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The timely and adequate expression of the SRY gene, located on Yp, will induce
a cascade of reactions resulting in the expression of several genes, mostly transcription
factors, and ultimately resulting in testicular development of the gonad in a male direc-
tion.17 Due to interaction with the pre-Sertoli cells, the gonocytes differentiate into
pre-spermatogonia, and as part of that process they move to the basal lamina, after
which they mature further (into spermatogonia). During this maturation process
they lose expression of the embryonic genes, and start enhanced expression of
additional genes – amongst others VASA (Mvh) and TSPY18 – indicative of further dif-
ferentiation along the male germ-cell lineage. Differences in this process have been
identified between mice and men.19 For example, c-KIT and OCT3/4 are still ex-
pressed in mouse spermatogonia, while OCT3/4 is absent in the human counterpart,
and c-KIT is immunohistochemically undetectable. In the absence of SRY expression,
the gonad will develop in the female direction, this being the default pathway. Germ
cells will form oocytes, which are blocked in their meiotic division.20 As part of
that process, they also lose expression of the aforementioned genes, including
OCT3/4.21,22
In addition to these morphological changes, the germ cells also undergo a unique
modification known as genomic imprinting.23,24 This is the difference in functionality be-
tween a haploid set of mammalian chromosomes, depending on the parental origin.
This modification is determined by epigenetic modifications such as DNA methylation.
The status of genomic imprinting is informative in distinguishing the various stages of
germ-cell development. The genomic imprinting pattern of PGCs/gonocytes is
erased25, while parental imprinting is established at later developmental stages of the
male germ-cell lineage.26
PRECURSOR LESIONS OF TYPE-II GCTS
The precursor of the type-II GCT of the testis is known as carcinoma in situ (CIS)/
intratubular germ-cell neoplasia unclassified (ITGCNU), initially linked to the develop-
ment of invasive type-II GCTs by Niels Skakkebaek3,27; it is also known as testicular
intratubular neoplasia (TIN).28 These cells show major characteristics of PGCs/gono-
cytes (see Figure 1), including their expression profile of genes and proteins such as
c-KIT, PLAP and OCT3/4 (see Figure 1A, left).29 In CIS/ITGCNU, OCT3/4 protein
is found in germ cells located at the basal lamina and under the tight junctions between
the Sertoli cells, whereas these specific features are not present under physiological
conditions. Of note is that in mouse PGCs OCT3/4 does not regulate the lineages
of differentiation, as reported in embryonic stem cells, both mouse and human16,30,
but it inhibits induction of apoptosis.31 It is tempting to speculate that this mechanism
also is operative in CIS/ITGCNU as well as seminoma cells, which are also OCT3/4-
positive.32–35 So far, in our hands, OCT3/4 is the most informative diagnostic marker
for CIS/ITGCNU and gonadoblastoma (see below), and for seminoma and embryonal
Practice points
 germ cells undergo specific maturation stages recognizable by morphology and
expression profile of genes and proteins as well as status of genomic imprinting
 OCT3/4 is a marker for primordial germ cells/gonocytes
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carcinoma of the adult testis. However, the application of this marker in postnatal pre-
pubertal gonads with possible delayed maturation of germ cells has to be interpreted
with caution, as will be discussed below.
In gonads of DSD patients, the precursor of the cancer might be CIS/ITGCNU or
gonadoblastoma, depending on the level of testicular differentiation.36–38 Gonadoblas-
toma is a lesion composed of a mixture of germ cells at different stages of maturation,
and of supportive pre-Sertoli/granulosa cells.37,39,40 At least some of the germ cells are
positive for OCT3/4, as are all the early invasive cells of seminoma (referred to as dys-
germinoma in dysgenetic gonads). These observations support the generally accepted
model that the precursor cells of type-II GCTs, both in the testis and in gonads of DSD
patients, are germ cells that are blocked in the early stages of development, i.e., PGCs/
gonocytes. The non-physiological histological position of these OCT3/4-positive CIS/
ITGCNU cells (see above) while expressing other embryonic markers, such as
NANOG41,42, at the basal lamina, under the tight junctions between the Sertoli cells,
is an interesting observation, the impact of which has not yet been elucidated. On the
basis of the extrapolation of epidemiological data, it is expected that all patients with
CIS/ITGCNU, and a suggested 50% with gonadoblastoma, will eventually develop
invasive type-II GCTs.43,44 These estimations are not based on empirical data. Most
recently, detailed histological investigation of gonads of DSD patients led to the iden-
tification of the precursor of gonadoblastoma, which was referred to as undifferenti-
ated gonadal tissue (UGT).45 Further characterization of these lesions will deepen our
knowledge about the earliest stages in the pathogenesis of type-II GCTs.
DELAY IN MATURATION AND MALIGNANT TRANSFORMATION:
A DIAGNOSTIC DILEMMA IN DSD
As indicated above, the most frequent precursor lesion of type-II GCTs is CIS/
ITGCNU, consisting of germ cells blocked in their physiological process of maturation,
and positioned at an abnormal localization. This observation has important implica-
tions. It means that in fact no specific markers are available to distinguish germ cells
that are delayed in their maturation from those undergoing malignant transformation.
This limits the application of these diagnostic markers in cases in which delayed germ-
cell maturation can be expected. This might result in an incorrect diagnosis of CIS/
ITGCNU and gonadoblastoma, resulting in over-treatment by gonadectomy, especially
in young patients. The current parameters used (by us) to diagnose malignant germ
cells in gonads of patients with hypovirilization are summarized in Table 2.36,46 Using
these criteria, a pre-CIS/ITGCNU has been identified in two patients, one with partial
androgen insensitivity and one with gonadal dysgenesis. Characterization of these cells
is a next step in the elucidation of the earliest stages of the process of type-II GCT
development.
Practice points
 the precursor of type-II GCTs in the testis is CIS/ITGCNU
 the precursor lesion of type-II GCTs in the dysgenetic gonad can be CIS/
ITGCNU or gonadoblastoma
OCT3/4 is positive in the malignant cells of these precursors
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It is of interest that a marked delay in germ-cell maturation is found only in fetal
gonadal tissue of male trisomy 21 patients and not in females.47 This might explain
the higher incidence of type-II GCTs in male trisomy 21 patients. In other words,
the identification of a new marker allowing unambiguous distinction between malig-
nant germ cells and germ cells delayed in their maturation might ultimately result in
a better insight into the individual risk of developing a type-II GCT and hence perhaps
in a more risk-adapted treatment of patients with DSD. Various studies are currently
being undertaken to identify such a marker. In particular the role of the Y chromo-
some in normal and malignant development is highly relevant and will be discussed
below.
THE ROLE OF OCT3/4 AND THE Y CHROMOSOME
IN TYPE-II GCTS
The ‘simple’ observation that type-II GCTs are the most frequent malignancies of the
testis in young adult Caucasian males links their development to male gonadal differen-
tiation and therefore to the Y chromosome. Interestingly, patients with Klinefelter
syndrome (47,XXY) have no increased risk for testicular type-II GCTs, but they do
for similar types of cancer of the mediastinal/thymus region.48 This might be related
to the fact that testicular germ cells disappear in XXY gonads, most likely because of
an improper microenvironment.49 The same may apply for the gonads of patients with
complete androgen insensitivity.36 Based on studies in patients with gonadoblastoma
or an invasive tumor, in whom Y chromosomal material has been identified in molecular
studies, it was concluded that a specific region of the Y chromosome is crucial for
Table 2. Additional criteria for the diagnosis of maturation delay and carcinoma in situ/intratubular
germ-cell neoplasia unclassified (CIS/ITGCNU) in XY individuals with under-virilization syndrome.
Maturation delay Transition CIS
Patient age <1 year Prepubertal >1 year
Position of OCT3/4þ
cells within the
seminiferous tubule
Luminally Luminally and on
the basal lamina
On the basal
lamina
Position of OCT3/4þ
cells throughout the gonad
Widespread Confined to a specific
region; the rest of the
gonad is free of positive
cells or displays
characteristics of
maturation delay
Confined to a
specific region;
the rest of the
gonad is free of
positive cells or
displays characteristics
of maturation delay
Practice points
 germ-cell maturation delay is a frequent finding in patients with DSD
 maturation-delayed germ cells cannot easily be distinguished from malignant
germ cells
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development of this type of cancer.50 It was found that the region around the centromere
of the Y chromosome – referred to as the GBY region – is of importance.51,52 A number
of candidate genes are located in this chromosomal fragment, including TSPY, which
stands for testis-specific protein on the Y chromosome.37,53–56 This multicopy
gene57–59 is expressed in germ cells.53 More interesting is the finding that it is present
in large amounts in CIS/ITGCNU and gonadoblastoma cells37 (see Figure 2A); the mech-
anism for this is unclear so far. A transgenic mouse model has been generated, in which
the human gene is integrated in multiple copies on the Y chromosome. However, up to
adult age there is no specific phenotype.60 Most of the precursor cells of the type-II
GCTs show a double-positive staining for TSPY and OCT3/4 (see Figure 2A). It is ex-
pected that TSPY is involved in regulation of proliferation.56,61 This is also based on bio-
chemical studies as well as deducted from structural characteristics. Based on these data,
an interesting model is emerging: it is the combination of inhibition of apoptosis, under
control of OCT3/4, and induction of proliferation, under control of TSPY (see
Figure 2B)37, that results in malignant transformation of embryonic germ cells, leading
to CIS/ITGCNU and gonadoblastoma.
An interesting recent observation is that although SRY induces the first step in tes-
ticular differentiation during embryogenesis, the relationship between the quantitative
presence of the Y chromosome (determined by in-situ hybridization techniques) and
testicular histology is not simple (Cools et al, submitted for publication). It remains to
be determined whether this is related to the functionality of the Y chromosome, i.e.,
to induction of the SRY-induced signaling cascade.
ADDITIONAL MALIGNANT ‘INTRINSIC’ CHARACTERISTICS
OF EMBRYONIC GERM CELLS
It is of interest that PGCs/gonocytes have a number of characteristics in common with
type-II GCTs, which are represented in the phenotype of cells undergoing malignant
transformation (see Figure 3A).62 These include the presence of telomerase activ-
ity63–67 and an erased pattern of genomic imprinting68–72, which has been related to
tumorigenesis in the mouse73, including development of a testicular seminoma. This
has never been reported in any animal so far.
One of the unsolved issues in the pathogenesis of type-II GCTs is the overall pres-
ence of wild-type P53 protein74–76, the most frequently inactivated gene in solid can-
cers.77 The requirement to inactivate P53 is (partly) due to the role the P53 protein
plays in overruling the mechanism of cellular senescence, induced for example by on-
cogenic stress.78 This discrepancy has recently been elucidated by our showing that
a specific set of microRNAs (i.e. hsa-miR 371–373) is expressed in seminomas and
the undifferentiated component of non-seminomas, in the presence of wild-type
P53.79 Expression of these microRNAs interferes with the process of translation of
the tumor suppressor LATS2 mRNA, which under physiological conditions blocks
the G1–S transition in the cell cycle. In the case of a mutation in P53, which is
a very rare phenomenon in type-II GCTs, the miRNA cluster 371–373 was not
Practice points
 presence of the GBY region is crucial for development of type-II GCTs
 TSPY is a likely candidate gene for the GBY region
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Figure 2. (A) Representative examples of immunohistochemical demonstration of TSPY (red staining) on
carcinoma in situ/intratubular germ-cell neoplasia unclassified (CIS/ITGCNU) and seminoma (upper left
panel) and embryonal carcinoma (upper right panel), as well as combined with OCT3/4 on CIS/ITGCNU
and seminoma (lower left panel) (TSPY¼ blue; OCT3/4¼ red), and on CIS/ITGCNU-containing testicular
parenchyma (lower right panel). Note the more intense TSPY staining in CIS/ITGCNU compared to normal
germ cells. (B) Schematic representation of the pathogenetic model of type-II germ-cell tumors (GCTs) in
the testis and dysgenetic gonad, in which OCT3/4 (indicated by a red nucleus: inhibition of apoptosis) and
TSPY (indicated by a blue cytoplasm: induction of proliferation) are involved. Note that the double-positive
germ cells are the cells that give rise to the invasive cancer. TSPY is frequently lost upon invasive growth.37
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Figure 3. (A) Summary of the different (intrinsic?) characteristics of embryonic germ cells (primordial germ
cells/gonocytes), i.e., telomerase activity, expression of stem-cell markers, erased pattern of genomic im-
printing, and expression of specific miRNAs, that are also reported to be related to the process of malignant
transformation. Due to the block in differentiation of these germ cells, these characteristics are retained in
carcinoma in situ/intratubular germ-cell neoplasia unclassified (CIS/ITGCNU) and gonadoblastoma (GB).
These precursor cells will progress to invasive tumors. (B) Schematic representation of the prediction
tree for development of type-II germ-cell tumors (GCTs) in patients with disorders of sex development
(DSD). The parameters to be investigated are morphology and histology of the gonadal tissue in the context
of the clinical findings of under-virilization, over-virilization, and gonadal dysgenesis. Proper distinction be-
tween delayed maturation and malignant transformation is of crucial importance. The presence of the
GBY region is represented by analysis of the TSPY protein.
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expressed. This was observed both in tumors in vivo as well as in tumor-derived cell
lines.
TUMOR RISK IN DIFFERENT SUBGROUPS OF DSD
Although overall DSD patients have an increased risk for development of type-II
GCTs, this risk is significantly different in the clinical subgroups. This has been
discussed in detail elsewhere1,38, but the major findings will be summarized here.
For better understanding, the following definitions are used.
 Gonadal dysgenesis: an incomplete or defective formation of the gonads, mostly due
to a disturbed process of migration of the germ cells and/or their correct organiza-
tion in the fetal gonadal ridge. This is due to structural or numerical anomalies of
the sex chromosomes or mutations in genes involved in the formation of the uro-
genital ridge and in sex determination of the bipotential gonad.38
 Hypervirilization refers to 46,XX individuals who are exposed to androgens – of en-
dogenous (due to genetic defects in enzymes involved in adrenal steroid hormone
production) or exogenous origin – during fetal life.
 Under-virilization refers to incomplete masculinization or the ambiguous or female
phenotype in an XY individual due to errors in testosterone biosynthesis or action
in androgen-dependent target tissues and unresponsiveness to stimulation from the
pituitary, or to defects in androgen-dependent target tissues.
The risk for type-II GCT development in the patients with DSD can be classified
into different levels: high, intermediate, low and unknown (see Table 3). It is clear
that for a number of entities it is based on a limited number of studies, sometimes in-
cluding small numbers of patients. Therefore, additional studies need to be performed
before a final conclusion can be drawn. In spite of this limitation, several statements
can already be made. At high risk are patients with gonadal dysgenesis with the
GBY region in their genome and intra-abdominal gonads, patients with partial andro-
gen insensitivity syndrome with non-scrotal gonads, and patients with Frasier and
Denys–Drash syndromes. The percentages found in the literature vary from 15 to
60%. At intermediate risk are patients with the Yþ (GBYþ) Turner syndrome and
those with 17b-hydroxysteroid dehydrogenase (17b-HSD) deficiency, gonadal dysgen-
esis (including the Y chromosome), or partial androgen insensitivity, the two latter
categories with scrotal gonads. The low-risk group includes patients with complete
androgen insensitivity as well as patients with ovotestis DSD and those with Turner
syndrome lacking an apparent Y chromosome in their karyotype. The unknown cate-
gory includes 5a-reductase deficiency and Leydig-cell hypoplasia, for which there are
insufficient data for proper analysis.
This first attempt to estimate the risk of the individual patient with DSD developing
a type-II GCT must be tested using additional cases in which proper criteria are used
for classifying patients in the different DSD entities, for histological characterization,
determination of the presence of CIS/ITGCNU and gonadoblastoma compared to
Practice point
 embryonic germ cells show characteristics of malignant cells
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delayed maturation. Using the aforementioned data, as well as the characterization of
the pre-malignant cells of type-II GCTs, a model is proposed to predict the risk for
malignant transformation in patients with DSD. This is schematically presented in
Figure 3B, and is currently being investigated for its clinical value. It is expected that
this model will be modified on the basis of additional information gathered in the var-
ious national and international studies.
CONCLUSIONS
Increasing knowledge of the characteristics of both normal and malignant germ cells
has become available. The invasive GCTs related to patients with DSD are the semi-
nomatous and non-seminomatous tumors, referred to as type-II GCTs. These origi-
nate from precursor lesions – i.e. CIS/ITGCNU and gonadoblastoma – containing
embryonic germ cells (PGC/gonocyte) blocked in their maturation. The formation
of CIS/ITGCNU or gonadoblastoma depends on the level of testicular development
of the gonad. The (pre)malignant cells can be identified using immunohistochemical
Table 3. Risk of type-II germinal cell tumors (GCTs) in the various categories of disorders of sex
development (DSD) patients, classified into high-, intermediate-, low- and no-risk groups.
Risk
group
Disorder Malignancy
risk (%)
Recommended
action
Studies
(n)
Patients
(n)
High GDa (þY)b intra-abdominal 15e35 Gonadectomyc 12 >350
PAIS non-scrotal 50 Gonadectomyc 2 24
Frasier 60 Gonadectomyc 1 15
DenyseDrash (þY) 40 Gonadectomyc 1 5
Intermediate Turner (þY) 12 Gonadectomyc 11 43
17b-HSD 28 Monitor 2 7
GD (þY)c Unknown Biopsyd and irradiation? 0 0
PAIS scrotal gonad Unknown Biopsyd and irradiation? 0 0
Low CAIS 2 Biopsyd and ??? 2 55
Ovotestis DSD 3 Testis tissue removal? 3 426
Turner (e Y) 1 None 11 557
No (?) 5a-reductase 0 Unresolved 1 3
Leydig cell hypoplasia 0 Unresolved 2
CAIS, complete androgen insensitivity syndrome; 17b-HSD, 17b-hydroxysteroid dehydrogenase defi-
ciency; PAIS, partial androgen insensitivity syndrome.
a Gonadal dysgenesis (including not further specified, 46XY, 46X/46XY, mixed, partial, complete).
b GBY region positive, including the TSPY gene.
c At time of diagnosis.
d At puberty, allowing investigation of at least 30 seminiferous tubules, with diagnosis preferably based
on OCT3/4 immunohistochemistry.
Practice point
 patients with DSD can be classified into high, intermediate, low, or unknown
risk groups for type-II GCTs
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detection of markers for embryonic germ cells, such as OCT3/4. It must be kept in
mind that these markers are not able to distinguish germ cells showing delayed mat-
uration from those that are malignantly transformed. Therefore, additional criteria
must be applied or a specific marker must be developed to prevent over-diagnosis.
Based on strict clinical and histological criteria, the various entities of patients with
DSD can be classified into different groups according to their risk for developing
type-II GCTs, i.e., high, intermediate, low (and so far unknown) risk groups. This
model must be tested, and possibly corrected after examination of additional series
of well-characterized patients.
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